79262-46-7
Chemical Structure
Savoxepine
Synonym(s): Cipazoxapine; CGP 19486A
- CAS No.: 79262-46-7
- Formula:C25H26N2O
- Molecular Weight:370.49
IUPAC Name: 3-(cyclopentylmethyl)-2,3,4,5-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-d]azepine-7-carbonitrile
InChIKey: MUAHMQUPOQGKOQ-UHFFFAOYSA-N
SMILES: N#CC1=CC=C2OC3=CC=CC=C3C(CCN(CC4)CC5CCCC5)=C4C2=C1
Biological Activity: Savoxepine (Cipazoxapine; CGP 19486A) is a dopamine antagonist with antipsychotic activity. Savoxepine preferentially blocks hippocampal dopamine D2 receptors and also inhibits dopamine-stimulated adenylate cyclase activity. Savoxepine shows strong interactions with α-adrenergic receptors, serotonin 5-HT2 receptors and histamine H1 receptors, and moderate interactions with α2-adrenergic receptors, histamine H2 receptors, serotonin 5-HT1 receptors and cholinergic muscarinic receptors. Savoxepine inhibits dopamine agonist-induced stereotyped behaviors in animals, induces catalepsy in animals, and antagonizes Apomorphine (HY-12723)-induced climbing behavior in mice. Savoxepine can be used in schizophrenia-related research[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Savoxepine | Savoxepine (Cipazoxapine; CGP 19486A) is a dopamine antagonist with antipsychotic activity. Savoxepine preferentially blocks hippocampal dopamine D2 receptors and also inhibits dopamine-stimulated adenylate cyclase activity. Savoxepine shows strong interactions with α-adrenergic receptors, serotonin 5-HT2 receptors and histamine H1 receptors, and moderate interactions with α2-adrenergic receptors, histamine H2 receptors, serotonin 5-HT1 receptors and cholinergic muscarinic receptors. Savoxepine inhibits dopamine agonist-induced stereotyped behaviors in animals, induces catalepsy in animals, and antagonizes Apomorphine (HY-12723)-induced climbing behavior in mice. Savoxepine can be used in schizophrenia-related research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Möller HJ, et al. Efficacy and tolerability of a new antipsychotic compound (savoxepine): results of a pilot-study. Pharmacopsychiatry. 1989 Jan;22(1):38-41. [Content Brief]
- [2]. Bischoff S, et al. Blockade of hippocampal dopamine (DA) receptors: a tool for antipsychotics with low extrapyramidal side effects. Progress in neuro-psychopharmacology & biological psychiatry. 1988;12(4):455-67. [Content Brief]
